Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials
| Autor: | Mao, C., Ji, D., Ding, Y., Zhang, Y., Song, W., Liu, L., Wu, Y., Song, L., Feng, X., Zhang, J., Cao, J., Xu, N. |
|---|---|
| Zdroj: | In ESMO Open June 2023 8(3) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|